These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16316335)

  • 1. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy.
    Hartmann B; Schmid G; Graeb C; Bruns CJ; Fischereder M; Jauch KW; Heeschen C; Guba M
    Kidney Int; 2005 Dec; 68(6):2593-8. PubMed ID: 16316335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring biological action of rapamycin in renal transplantation.
    Leogrande D; Teutonico A; Ranieri E; Saldarelli M; Gesualdo L; Schena FP; Di Paolo S
    Am J Kidney Dis; 2007 Aug; 50(2):314-25. PubMed ID: 17660033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.
    Wang JY; Fan H
    Chin Med J (Engl); 2015 Mar; 128(5):664-9. PubMed ID: 25698201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of P70S6 kinase phosphorylation after liver transplantation by phospho-flow cytometry].
    Wang J; Fan H
    Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(48):3809-12. PubMed ID: 25623311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.
    Chiang GG; Abraham RT
    J Biol Chem; 2005 Jul; 280(27):25485-90. PubMed ID: 15899889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition.
    Hartmann B; He X; Keller F; Fischereder M; Guba M; Schmid H
    Ther Drug Monit; 2013 Apr; 35(2):233-9. PubMed ID: 23503450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.
    Woillard JB; Kamar N; Rousseau A; Rostaing L; Marquet P; Picard N
    Pharmacogenet Genomics; 2012 Oct; 22(10):725-32. PubMed ID: 22863900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
    Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
    Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
    Huber S; Bruns CJ; Schmid G; Hermann PC; Conrad C; Niess H; Huss R; Graeb C; Jauch KW; Heeschen C; Guba M
    Kidney Int; 2007 Apr; 71(8):771-7. PubMed ID: 17299523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
    Stallone G; Schena A; Infante B; Di Paolo S; Loverre A; Maggio G; Ranieri E; Gesualdo L; Schena FP; Grandaliano G
    N Engl J Med; 2005 Mar; 352(13):1317-23. PubMed ID: 15800227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates.
    Dekter HE; Romijn FP; Temmink WP; van Pelt J; de Fijter JW; Smit NP
    Anal Biochem; 2010 Aug; 403(1-2):79-87. PubMed ID: 20417611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
    Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
    Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological action of rapamycin in renal transplantation.
    Weichhart T; Werzowa J; Hörl WH; Säemann MD
    Am J Kidney Dis; 2008 Mar; 51(3):531; author reply 531-2. PubMed ID: 18295073
    [No Abstract]   [Full Text] [Related]  

  • 17. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
    Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
    Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunosuppressant tributyltin oxide blocks the mTOR pathway, like rapamycin, albeit by a different mechanism.
    Osman AM; van Loveren H
    J Appl Toxicol; 2014 Dec; 34(12):1361-7. PubMed ID: 24375594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
    Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
    Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.